Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Mild to moderate hypertension (adjunctive therapy),Psychotic disorders (off-label),Tardive dyskinesia (off-label),Huntington disease (off-label)
Hypertension
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation; specific CYP enzymes are not well characterized.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
~96% bound to plasma proteins (albumin and lipoproteins).
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
Vd 9.4 L/kg, indicating extensive tissue binding (particularly adrenergic neurons, brain, adipose).
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 30–40% due to extensive first-pass metabolism; IM/IV: 100%.
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
No specific dose adjustment; use cautiously in severe renal impairment (Cr Cl <30 m L/min) due to risk of hypotension and CNS effects.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh Class B or C: contraindicated; use not recommended.
Hypertension: 0.02 mg/kg/day orally divided every 6–12 hours; maximum 0.25 mg/day. Psychosis: not recommended.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at 0.05 mg orally once daily; increase slowly due to increased sensitivity and risk of hypotension, sedation, and depression.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
May cause severe depression with risk of suicide (discontinue if depression occurs),Use with caution in patients with history of peptic ulcer disease (increases gastric acid secretion),Use with caution in patients with renal impairment (may reduce renal blood flow),Avoid concomitant use with MAOIs (risk of hypertensive crisis),Electroshock therapy: discontinue reserpine 7-14 days prior,May cause biliary colic in patients with gallstones,May exacerbate arrhythmias in patients with cardiac disease
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Hypersensitivity to reserpine or any component,History of depression (especially suicidal),Active peptic ulcer disease,Ulcerative colitis,Electroconvulsive therapy (within 7-14 days),Concurrent MAO inhibitor therapy (or within 2 weeks of discontinuation),Pheochromocytoma
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, yeast extracts) as reserpine can potentiate pressor responses, leading to hypertensive crisis. Alcohol may increase sedative effects. Grapefruit juice may alter drug metabolism; limit intake.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: risk of neonatal bradycardia, hypotonia, lethargy, and respiratory depression. Use only if benefits outweigh risks.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Reserpine is excreted into breast milk. M/P ratio not established. Risk of infant bradycardia, GI upset, and nasal congestion. Not recommended during breastfeeding.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
No specific dose adjustment guidelines. Consider lower starting doses due to increased sensitivity. Monitor maternal blood pressure closely to avoid hypotension.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Serpasil (reserpine) is an antihypertensive and antipsychotic that depletes catecholamines from peripheral sympathetic nerve endings and CNS. Onset is slow (3-6 days) and effects persist for weeks after discontinuation. Monitor for depression, especially in patients with history. Avoid in patients requiring MAOIs due to hypertensive crisis risk. Use with caution in peptic ulcer disease due to increased gastric acid secretion. Bradycardia and nasal congestion are common side effects.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take exactly as prescribed; do not stop suddenly as blood pressure may rise rapidly.,Report any symptoms of depression, mood changes, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold or allergy medications containing decongestants.,May cause drowsiness or dizziness; avoid driving until you know how the drug affects you.,Contact your healthcare provider if you experience slow heartbeat, fainting, or severe stomach pain.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL vs ALDORIL D30, answered by our medical review team.
SERPASIL is a Antihypertensive that works by Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL and ALDORIL D30 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL is: Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL is classified as Category C. Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: ris. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.